Oxford Immunotec Global PLC (OXFD) Could Burn Your Portfolio. The Stock Formed Bearish Wedge Down Chart Pattern

December 7, 2017 - By Adrian Mccoy

Investors sentiment decreased to 1.27 in 2017 Q2. Its down 0.56, from 1.83 in 2017Q1. It worsened, as 10 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 8 funds opened positions while 30 raised stakes. 19.91 million shares or 1.07% more from 19.70 million shares in 2017Q1 were reported.
Royal Natl Bank Of Canada stated it has 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Kornitzer Cap Mgmt Inc Ks holds 0.02% or 60,300 shares in its portfolio. C Worldwide Grp Hldgs A S holds 0.05% or 182,148 shares. Cortina Asset Management Limited holds 499,525 shares or 0.36% of its portfolio. Northwestern Mutual Wealth Co accumulated 0% or 193 shares. California State Teachers Retirement Sys reported 40,046 shares. Essex Mgmt Lc holds 0.34% or 141,197 shares. Endurant Cap Mgmt Limited Partnership has invested 3.57% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Penn Cap Mngmt Co Incorporated invested in 179,415 shares or 0.22% of the stock. 227,400 were reported by Waddell & Reed Fin. Neuberger Berman Gp Limited Liability Corp holds 104,257 shares. Millennium Mgmt Ltd Liability Com holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 38,944 shares. Rhumbline Advisers has invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Ameritas Ptnrs Inc reported 1,917 shares. Spark Invest Management Ltd Liability Co owns 150,500 shares.

Since June 15, 2017, it had 0 insider purchases, and 1 sale for $61,305 activity.

The stock of Oxford Immunotec Global PLC (OXFD) formed a down wedge with $13.36 target or 4.00 % below today’s $13.92 share price. The 6 months wedge indicates high risk for the $357.12M company. If the $13.36 price target is reached, the company will be worth $14.28 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 1.90% or $0.27 during the last trading session, reaching $13.92. About 105,114 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since December 8, 2016 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.34 EPS, down 54.55 % or $0.12 from last year’s $-0.22 per share. After $-0.24 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 41.67 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 8 analyst reports since July 19, 2017 according to SRatingsIntel. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Wednesday, July 19. Cowen & Co has “Buy” rating and $1900 target. Cowen & Co maintained the stock with “Buy” rating in Tuesday, October 31 report. The stock has “Buy” rating by Robert W. Baird on Thursday, October 19. As per Wednesday, August 16, the company rating was maintained by Cowen & Co. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Wednesday, September 27. Cowen & Co has “Buy” rating and $19.0 target. The rating was initiated by BTIG Research on Thursday, September 28 with “Buy”. On Tuesday, October 31 the stock rating was maintained by Robert W. Baird with “Buy”.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Seekingalpha.com which released: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q2 2017 Results …” on August 01, 2017, also Globenewswire.com with their article: “Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference” published on November 10, 2017, Seekingalpha.com published: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2017 Results …” on May 02, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Globenewswire.com and their article: “Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in …” published on June 22, 2017 as well as Globenewswire.com‘s news article titled: “Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer” with publication date: July 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.